GTCR to acquire Sterigenics International

NewsGuard 100/100 Score

GTCR, a leading private equity firm, today announced it has signed a definitive agreement with Silverfleet Capital and PPM America Capital Partners to acquire Sterigenics International, Inc. ("Sterigenics"), the leading global provider of contract sterilization and ionization services for medical devices, food products, and advanced applications.

The transaction will drive the continued expansion of Sterigenics' service offering globally. Sterigenics is the sole provider of contract sterilization and ionization services on a global basis, with a network of 38 service centers across North America, Europe, and Asia. The Company provides its customers with comprehensive sterilization solutions, offering technology in all leading sterilization modalities and complementary value-added services. Sterigenics has earned a reputation among its customer base for providing high-quality and cost-effective solutions tailored to customer needs.

"GTCR's extensive experience investing in leading companies in both the healthcare and business services sectors gives us a unique perspective on the Sterigenics business," said Dean Mihas, Principal at GTCR. "We look forward to partnering with the Sterigenics management team to execute on their plan to grow the business and extend its leadership position."

"GTCR's investment is a validation of what we have built at Sterigenics," noted David Meyer, CEO of Sterigenics. "We are excited to begin a new collaboration with an equity partner committed to our growth as we pursue our strategic goals and expand our service offering to our customers."

Jefferies & Company, Bank of America Merrill Lynch and UBS advised GTCR on the transaction, and Kirkland & Ellis LLP served as legal counsel to GTCR. J.P. Morgan, Bank of America Merrill Lynch, UBS, and Morgan Stanley have agreed to provide debt financing in connection with the transaction. GTCR's investment in Sterigenics will be made from GTCR Fund IX, a private equity fund with $2.75 billion of committed capital. The transaction is expected to close in the first half of 2011.

Source:

GTCR

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Korean fermented food Doenjang shows promise in alleviating menopausal symptoms